Consistent with the results of a previous study [11], our results showed that pretreatment with linsitinib significantly reduced 100 ng/ml IGF-1- stimulated HA secretion by OFs from TAO patients (Fig 3). This evidence concerns the gene IGF1 and thromboangiitis obliterans.